Our top pick for
Alphatec Holdings Inc is a medical devices business based in the US. Alphatec shares (ATEC) are listed on the NASDAQ and all prices are listed in US Dollars. Alphatec employs 296 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$12.09|
|52-week range||$8.27 - $19.36|
|50-day moving average||$13.39|
|200-day moving average||$14.49|
|Wall St. target price||$21.81|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.27|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||-0.90%|
|1 month (2021-09-21)||-13.89%|
|3 months (2021-07-23)||-14.32%|
|6 months (2021-04-23)||-27.65%|
|1 year (2020-10-22)||29.30%|
|2 years (2019-10-22)||112.11%|
|3 years (2018-10-22)||276.64%|
|5 years (2016-10-21)||94.69%|
|Revenue TTM||$191.5 million|
|Gross profit TTM||$102.5 million|
|Return on assets TTM||-14.15%|
|Return on equity TTM||-74.1%|
|Market capitalisation||$1.2 billion|
TTM: trailing 12 months
There are currently 6.3 million Alphatec shares held short by investors – that's known as Alphatec's "short interest". This figure is 11% up from 5.7 million last month.
There are a few different ways that this level of interest in shorting Alphatec shares can be evaluated.
Alphatec's "short interest ratio" (SIR) is the quantity of Alphatec shares currently shorted divided by the average quantity of Alphatec shares traded daily (recently around 1.0 million). Alphatec's SIR currently stands at 6.04. In other words for every 100,000 Alphatec shares traded daily on the market, roughly 6040 shares are currently held short.
However Alphatec's short interest can also be evaluated against the total number of Alphatec shares, or, against the total number of tradable Alphatec shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alphatec's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Alphatec shares in existence, roughly 60 shares are currently held short) or 0.0926% of the tradable shares (for every 100,000 tradable Alphatec shares, roughly 93 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Alphatec.
Find out more about how you can short Alphatec stock.
We're not expecting Alphatec to pay a dividend over the next 12 months.
Alphatec's shares were split on a 1:12 basis on 24 August 2016. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alphatec shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Alphatec shares which in turn could have impacted Alphatec's share price.
Over the last 12 months, Alphatec's shares have ranged in value from as little as $8.27 up to $19.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alphatec's is 1.8048. This would suggest that Alphatec's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Alphatec Holdings, Inc. , a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; squadron lateral retractor designed to maximize patient outcomes; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System designed to improve surgical efficiency without compromising accuracy. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; solanas posterior cervico/thoracic fixation system and avalon occipital plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. Further, it develops EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.